Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered

Author:
David S. Ettinger
Search for other papers by David S. Ettinger in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

David S. Ettinger, MD, is the Alex Grass Professor of Oncology and Professor of Medicine, Otolaryngology-Head and Neck Surgery, Obstetrics and Gynecology, and Radiation Oncology and Molecular Radiation Sciences at The Johns Hopkins University School of Medicine.

Dr. Ettinger has served as a consultant for dozens of organizations. He is widely published and has authored or co-authored more than 200 articles for journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer.

Dr. Ettinger is a member of the NCCN Lung Cancer Screening Panel and Chair of the NCCN Non–Small Cell Lung Cancer Panel, Thymic Carcinomas Panel, Occult Primary Cancers Panel, and Antiemesis Panel. He is a member of the editorial board for JNCCN and serves as a member of several committees and advisory boards for the NCCN Oncology Research Program. Dr. Ettinger also serves as the Chair of the NCCN Guidelines Steering Committee. He also serves on the NCCN International Program Steering Committee, the NCCN Educational Programs Advisory Committee, and the NCCN Board of Directors.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • Collapse
  • Expand
  • 1.

    Ettinger DS, Cox JD, Ginsberg RJ et al.. NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. Oncology 1996;10(Suppl 11):81111.

  • 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016;66:730.

  • 3.

    Ferlay J, Soerjomataram I, Ervik M et al.. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Accessed July 20, 2016.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015;373:14901492.

  • 5.

    Brahmer J, Reckamp KL, Baas P et al.. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123135.

  • 6.

    Gettinger SN, Horn L, Gandhi L et al.. Overall survival and long-term study of nivolumab (anti-programmed death 1 antibody, BMS 936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:20042012.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Borghaei H, Paz-Ares L, Horn L et al.. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:16271639.

  • 8.

    Garon EB, Rizvi NA, Hui R et al.. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:20182028.

  • 9.

    Herbst RS, Baas P, Kim DW et al.. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:15401550.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Postow M, Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. Available at: http://www.uptodate.com/contents/toxicities-associated-with-checkpoint-inhibitor-immunotherapy. Accessed July 20, 2016.

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1044 360 53
PDF Downloads 317 57 3
EPUB Downloads 0 0 0